Phathom Pharmaceuticals, Inc. (PHAT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q4 '23: 682K Q1 '24: 2.6M Q2 '24: 9.9M Q3 '24: 26.3M Q4 '24: 55.3M Q1 '25: 81.9M Q2 '25: 114M Q3 '25: 147.2M Q4 '25: 175.1M Q1 '26: 204.9M Q2 '26: 239.7M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

0 70M 140M 210M Q4 '23: 515K Q1 '24: 2M Q2 '24: 7.9M Q3 '24: 21.9M Q4 '24: 47.3M Q1 '25: 70.6M Q2 '25: 99.1M Q3 '25: 128.4M Q4 '25: 152.5M Q1 '26: 174M Q2 '26: 198.7M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -154.5M Q4 '21: -135.1M Q1 '22: -139.4M Q2 '22: -149.4M Q3 '22: -158.8M Q4 '22: -172.4M Q1 '23: -164.6M Q2 '23: -150.9M Q3 '23: -144.1M Q4 '23: -167.3M Q1 '24: -207.2M Q2 '24: -252.8M Q3 '24: -287.9M Q4 '24: -277.5M Q1 '25: -286.4M Q2 '25: -269M Q3 '25: -213.5M Q4 '25: -160M Q1 '26: -96.6M Q2 '26: -40.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -161.8M Q4 '21: -143.9M Q1 '22: -149.7M Q2 '22: -164.1M Q3 '22: -178.5M Q4 '22: -197.7M Q1 '23: -194.9M Q2 '23: -184.9M Q3 '23: -177.1M Q4 '23: -201.6M Q1 '24: -246.6M Q2 '24: -297.1M Q3 '24: -339.4M Q4 '24: -334.3M Q1 '25: -345.8M Q2 '25: -330.2M Q3 '25: -274.6M Q4 '25: -221.2M Q1 '26: -157.3M Q2 '26: -99.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '23: 167K Q1 '24: 593K Q2 '24: 2M Q3 '24: 4.3M Q4 '24: 8M Q1 '25: 11.3M Q2 '25: 14.9M Q3 '25: 18.8M Q4 '25: 22.6M Q1 '26: 30.9M Q2 '26: 40.9M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -135.4M Q4 '21: -148.5M Q1 '22: -143.4M Q2 '22: -140.8M Q3 '22: -146.8M Q4 '22: -146.5M Q1 '23: -141.4M Q2 '23: -137.9M Q3 '23: -134.8M Q4 '23: -137.6M Q1 '24: -166.9M Q2 '24: -215.5M Q3 '24: -247.1M Q4 '24: -266.8M Q1 '25: -282.7M Q2 '25: -274.7M Q3 '25: -225.2M Q4 '25: -166.8M Q1 '26: -97.5M Q2 '26: -36.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -135.7M Q4 '21: -148.8M Q1 '22: -143.7M Q2 '22: -141.4M Q3 '22: -147.5M Q4 '22: -147.6M Q1 '23: -142.6M Q2 '23: -138.7M Q3 '23: -136.4M Q4 '23: -139.2M Q1 '24: -168.4M Q2 '24: -217M Q3 '24: -247.7M Q4 '24: -266.9M Q1 '25: -282.8M Q2 '25: -274.9M Q3 '25: -225.4M Q4 '25: -167M Q1 '26: -97.8M Q2 '26: -36.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 36.6M Q3 '21: 37.3M Q1 '22: 38M Q2 '22: 38.3M Q3 '22: 38.8M Q1 '23: 42.4M Q2 '23: 48.5M Q3 '23: 56.8M Q1 '24: 58.4M Q2 '24: 58.6M Q3 '24: 64.6M Q1 '25: 72M Q2 '25: 72.5M Q3 '25: 73.4M Q1 '26: 82.1M Q2 '26: 83.7M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -4.52 Q4 '21: -3.89 Q1 '22: -4.00 Q2 '22: -4.33 Q3 '22: -4.67 Q4 '22: -5.05 Q1 '23: -4.87 Q2 '23: -4.38 Q3 '23: -3.82 Q4 '23: -3.94 Q1 '24: -4.47 Q2 '24: -5.19 Q3 '24: -5.75 Q4 '24: -5.30 Q1 '25: -5.19 Q2 '25: -4.68 Q3 '25: -3.77 Q4 '25: -3.04 Q1 '26: -2.10 Q2 '26: -1.26 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.